Company intelligence / Profile preview

Propelle Therapeutics

Pittsboro, North Carolina, United Statesresearchgate.net ↗

Ownership: Private
Development stage: Preclinical

Overview

PRL-02 (abiraterone decanoate) is in Phase 1 clinical trials with plans to enter Phase 2a in 2024. It's a novel, long-acting prodrug of abiraterone that is expected to achieve high concentrations in target tissues.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

PAS-IL-1Ra

Pre-clinical

Indications: Chronic recurrent multifocal osteomyelitis, Cryopyrin-associated periodic syndromes, Muckle-Wells syndrome, Neonatal-onset multisystem inflammatory disease, Macrophage activation syndrome, Lung cancer, Breast cancer, Melanoma

Beyond the preview

Go deeper on Propelle Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propelle Therapeutics.

Explore the full profile